Efficacy and Mechanism of IPSRT for Bipolar II Disorder

Starting soon · Phase 2

Conditions studied: Bipolar Disorder II

In brief

This project is based on the biphasic instability model and social timing theory, utilizing IPSRT to help regulate social interactions and establish regular daily habits, alleviate emotional symptoms, and prevent. The included patients with bipolar II disorder who did not take medication for the first time or relapsed within the past month were randomly divided into a medication only group (Q group), a only IPSRT group (I group). Group Q received treatment with quetiapine alone (starting at 50mg/day, with an additional 50mg to 300mg/day per week, and the dosage can be flexibly adjusted); Group I received 12 weeks of interpersonal and social rhythm therapy (12 sessions, once a week, 40 minutes each time, with relatively fixed tasks and agendas for each meeting). Compare the changes in various clinical evaluation scales and skin potential before and after treatment, explore the safety and effectiveness of drug therapy and psychotherapy for patients with bipolar II disorder with rhythm disorders, and investigate the potential biological mechanism of IPSRT by collecting data on salivary cortisol and melatonin, peripheral circadian rhythm genes (PER1/PER2/PER3/BMAL1), and magnetic resonance.

Key facts

Study ID

NCT07654348

Run by

First Affiliated Hospital of Zhejiang University

People needed

216

Starts

2026-07-01

Expected to finish

2029-07-01

Last updated by the study team

2026-06-17

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1: a primary diagnosis of bipolar II disorder in accordance with DSM-V criteria, in a current major depressive episode;
• 2: scoring ≥17 on the 17-item Hamilton Rating Scale for Depression (HAMD-17)
• 3: scoring <12 on the Young Mania Rating Scale (YMRS)
• 4: medication-free (≥4 weeks without psychotropics)
• 5: with rhythm disturbance, scoring >26 on the Biological Rhythm Interview for Neuropsychiatry (BRIAN)
• 6: Understand written language and be able to conduct questionnaire survey
• 7: 18 to 60 years old, gender is not limited
• 8: the patient voluntarily participates, signs a written informed consent form, is willing to participate in the study and undergo evaluation
• 9: Han Chinese
• 10: Right-handedness

You may not qualify if…

• 1: diseases that may significantly increase research risks or interfere with the evaluation of results
• 2: patients with rapid-cycling bipolar disorder (with >4 episodes within the past year);
• 3: any psychiatric or organic mental disorder, bipolar I disorder (BD I), current alcohol or drug dependence, borderline or antisocial personality disorder
• 4: patients currently receiving any psychological treatment or melatonin treatment intervention
• 5: patients with active suicidal ideation, HAMD-17 item 3 score ≥3
• 6: pregnant
• 7: patients with metal objects in the body (pacemaker, cochlear implant, implanted teeth, braces, metal foreign bodies, cardiac stent/intravascular coil, orthopedic steel plate, etc.) and other MRI examination contraindications (claustrophobia or inability to cooperate with the examination).

Where it is running

• The First Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.